The technology is a soft, resilient hemostatic biofoam useful for treating both intracavity and surface wounds. The material conforms to irregular wound shapes to stop bleeding and transitions to a porous gel protecting newly formed tissue. It is naturally bioabsorbable and composed of low cost, FDA-approved ingredients.
Technology provides an improved wound care solution for many applications: traumatic wounds, surgical wounds, surface wounds, and possibly even negative-pressure wound healing. Because the material is also edible and a tissue scaffold, applications may extend into engineered foods involving animal tissue, such as in vivo meat production.
The product can be used as a traditional wound care product (US market $2.3 billion per year), an active wound care product (US market $1.6 billion per year), and an advanced wound care (US market $2.2 billion per year). It may also be an ideal foam for negative pressure wound healing (US market for therapy $1 billion per year).
US patent application 14/198,415 “Composite Materials.” EV patent application 14760576.0